Advanced Prostate Cancer
4,279 members4,119 posts

"A kiss of death for prostate cancer"

Although most of this report dated last Friday, Jan 5th, 2018, is Chinese to me, it sounds promising, so thought I'd share:

ustoo.org/News-Page/1xKTCUI...**

Newswire (Published: Tuesday, January 9, 2018, Received: Friday, January 5, 2018, 12:04:47 PM CST)

Word Count: 298

By a News Reporter-Staff News Editor at Cancer Weekly -- Hokkaido University researchers have uncovered a cellular protein that stabilizes a tumor promoting signaling pathway, suggesting a new target to treat prostate cancer (see also Hokkaido University).

The drug Gefitinib is used to treat breast, lung, and other cancers by inhibiting epidermal growth factor receptor (EGFR) signaling, but it has only a limited effect on prostate cancer. EGFR, present on the cell membrane, is involved in cell proliferation and the development of dermis, lung, and digestive tissues. When a mutation causes its over-activation, it can lead to increased cell proliferation and tumor formation.

Tadashi Matsuda of Hokkaido University and his colleagues in Japan investigated human prostate cancer cells to determine if there is an unknown up-regulation mechanism in the EGFR pathway.

When EGFR is attached to a small protein called ubiquitin, it is given "the kiss of death" and tagged for degradation inside the cell. This tagging process is facilitated by a protein called c-CBL. The degradation of EGFR leads to less signaling from the receptor and reduced cell proliferation.

Matsuda and his team found that signal-transducing adaptor protein-2 (STAP-2) stabilizes EGFR by inhibiting its c-CBL-mediated ubiquitination. Furthermore, when the team suppressed STAP-2, the prostate cancer cells showed reduced proliferation and did not form a tumor when transplanted into mice.

"STAP-2 inhibitors could play a role in treating Gefitinib-resistant prostate cancers. Further studies on STAP-2 will provide new insights into cancer physiology and support the development of anticancer therapies," says Tadashi Matsuda. The study was published in the Journal of Biological Chemistry.

Keywords for this news article include: Cancer, Oncology, Cell Proliferation, Health and Medicine, Hokkaido University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

Companies

Hokkaido University

Places

Eastern Asia

Japan

Asia

Subjects

Science and Technology

Scientific Research

Health and Wellness

Medical Conditions and Diseases

Cancer

Prostate Cancer

Men's Health Issues

Prostate Cancer

Treatments and Therapies

Medicinal Drugs

Growth Factors and Cytokines

5 Replies
oldestnewest

JLS

These are all sounds good , what you saying , is it the result of a clinical study ? How long this works , before cancer cell start mutating ? I couldn’t open the link.

Reply

Sounds promising. The link doesn't work but I found this. sciencedaily.com/releases/2...

Reply

Good morning JLS. Very interesting article. I wonder how long it will take before this treatment protocol will undergo human clinical trials. If nothing else, it gives us all hope, and the knowledge that researchers are constantly searching for new weapons for our fight against PCa.

Reply

Any good news on new treatments is great news !

Reply

Read it ---you beat me to the Post.

Nalakrats

Reply